Enzymes and Enzyme Kinetics

Catalysis and Activation Energy

Enzymes accelerate reactions by lowering the activation energy (Ea)—the energy barrier between reactants and the transition state. They do NOT change ΔG (the free-energy difference between reactants and products), ΔH, ΔS, or the equilibrium constant Keq. Enzymes stabilize the transition state through specific interactions (hydrogen bonds, electrostatic interactions, acid-base catalysis, covalent catalysis, metal-ion catalysis) in the active site—a three-dimensional pocket shaped to complement the transition state, not the substrate. The active site provides: proximity and orientation effects (bringing substrates together in the correct orientation), strain/distortion (binding strains substrate bonds toward the transition-state geometry), and microenvironment effects (active-site residues with perturbed pKa values, hydrophobic pockets excluding water). Cofactors are non-protein components required for catalysis: metal ions (Mg2+, Zn2+, Fe2+) or coenzymes (organic molecules, often derived from vitamins—NAD+ from niacin, FAD from riboflavin, coenzyme A from pantothenic acid, TPP from thiamine). Holoenzyme = apoenzyme (protein portion) + cofactor. Prosthetic groups are tightly or covalently bound cofactors (e.g., heme in cytochromes, FAD in succinate dehydrogenase). The rate enhancement achieved by enzymes is enormous—typically 10^6 to 10^12-fold over the uncatalyzed reaction.

Michaelis-Menten Kinetics

The Michaelis-Menten model describes enzyme kinetics under the steady-state assumption: the concentration of the enzyme-substrate complex [ES] is constant because the rate of ES formation equals the rate of its breakdown. The model assumes: (1) initial velocity conditions ([P] ≈ 0, reverse reaction negligible), (2) [S] >> [E] (free [S] ≈ total [S]), and (3) steady state. The Michaelis-Menten equation: V0 = Vmax[S] / (Km + [S]). At low [S] ([S] << Km): V0 ≈ (Vmax/Km)[S]—the reaction is first-order with respect to substrate. At high [S] ([S] >> Km): V0 ≈ Vmax—the reaction is zero-order, independent of [S]; enzyme is saturated. At [S] = Km: V0 = Vmax/2. Km is the substrate concentration at half-maximal velocity; it reflects the apparent affinity of the enzyme for its substrate (lower Km = higher affinity, reaches half Vmax at lower [S]). However, Km is not a pure dissociation constant—it equals (k₋₁ + kcat)/k₁. Only when kcat << k₋₁ does Km approximate Kd. kcat (turnover number) = Vmax/[E]total: the maximum number of substrate molecules converted to product per enzyme active site per unit time (units: s⁻¹). Catalytic efficiency is measured by kcat/Km (units: M⁻¹s⁻¹), which reflects both binding and catalysis. The diffusion-limited maximum for kcat/Km is ~10^8–10^9 M⁻¹s⁻¹; enzymes near this limit (e.g., carbonic anhydrase, catalase) are 'catalytically perfect'—every substrate encounter leads to product.

Vmax, Km, and kcat

These three parameters are the quantitative language of enzyme kinetics, and the MCAT expects you to interpret all of them from graphs and tables. Vmax: the maximum reaction velocity when all enzyme active sites are saturated with substrate. Vmax depends on [E]total (more enzyme = higher Vmax). On a Michaelis-Menten plot (V0 vs. [S]), Vmax is the horizontal asymptote. On a Lineweaver-Burk plot (1/V0 vs. 1/[S]), Vmax is 1/y-intercept. Km: the substrate concentration at Vmax/2. On a Michaelis-Menten plot, find Vmax/2 on the y-axis and read the corresponding [S] on the x-axis. On a Lineweaver-Burk plot, Km = −1/x-intercept (but note the negative x-intercept). The Lineweaver-Burk equation: 1/V0 = (Km/Vmax)(1/[S]) + 1/Vmax. This linear transformation enables visual diagnosis of inhibition type. Slope = Km/Vmax, y-intercept = 1/Vmax, x-intercept = −1/Km. kcat = Vmax/[E]total. It represents the catalytic power of a single enzyme molecule. For enzymes with multiple active sites, use the concentration of active sites, not enzyme molecules. Units: kcat in s⁻¹. Catalytic efficiency = kcat/Km. An enzyme with kcat/Km near the diffusion limit (~10^8) is limited only by how fast substrate can diffuse to the active site—the reaction occurs on every encounter. When comparing two substrates for the same enzyme, the one with higher kcat/Km is the preferred substrate. When comparing two enzymes for the same substrate, higher kcat/Km means better catalytic efficiency.

Competitive, Noncompetitive, Uncompetitive, and Mixed Inhibition

The four classical inhibition types are distinguished by their effects on Km and Vmax, visualized on Lineweaver-Burk plots. Competitive inhibition: inhibitor resembles the substrate and binds to the active site, competing directly. Effect: Km increases (apparent affinity decreases because more substrate is needed to outcompete the inhibitor), Vmax unchanged (at infinite [S], substrate outcompetes inhibitor entirely). Lineweaver-Burk: lines intersect at the y-axis (same Vmax), x-intercept shifts right (higher Km). Example: statins as competitive inhibitors of HMG-CoA reductase; methotrexate as competitive inhibitor of dihydrofolate reductase. Noncompetitive inhibition: inhibitor binds to an allosteric site (not the active site) with equal affinity for both E and ES complex. Effect: Vmax decreases (fewer functional enzyme molecules), Km unchanged (substrate binding is unaffected because the inhibitor binds elsewhere). Lineweaver-Burk: lines intersect at the x-axis (same Km), y-intercept shifts up (lower Vmax). Pure noncompetitive is rare; most 'noncompetitive' inhibitors are actually mixed. Uncompetitive inhibition: inhibitor binds ONLY to the ES complex (not free enzyme), typically at high substrate concentrations. Effect: both Vmax and Km decrease by the same factor, so the ratio Vmax/Km (and thus slope Km/Vmax on Lineweaver-Burk) is unchanged. Lineweaver-Burk: parallel lines (same slope). Mixed inhibition: inhibitor binds both E and ES, but with different affinities. Effect: Vmax decreases; Km may increase (prefers E) or decrease (prefers ES). Lineweaver-Burk: lines intersect at a point that is neither on the x- nor y-axis. All inhibition is reversible (non-covalent) in this classification. Irreversible inhibitors (e.g., aspirin covalently acetylating COX, organophosphates binding acetylcholinesterase, penicillin binding transpeptidase) permanently inactivate the enzyme—effectively reducing [E]total and thus Vmax.

Allosteric Regulation

Allosteric enzymes have multiple subunits and binding sites: an active site for the substrate and one or more allosteric (regulatory) sites for effector molecules. Allosteric effectors bind non-covalently at sites distinct from the active site and stabilize either the more active R (relaxed) state or the less active T (tense) state of the enzyme—this is the concerted (MWC) model. Allosteric activators stabilize the R state, shifting the equilibrium toward higher activity. Allosteric inhibitors stabilize the T state, reducing activity. Allosteric enzymes display sigmoidal (S-shaped) kinetics (not hyperbolic), reflecting cooperativity between subunits: substrate binding to one active site increases the affinity of neighboring active sites (positive cooperativity). The Hill equation describes cooperativity: log(V0/(Vmax−V0)) = nH log[S] − log(K'), where nH is the Hill coefficient. nH = 1: no cooperativity (Michaelis-Menten). nH > 1: positive cooperativity. nH < 1: negative cooperativity. Hemoglobin (though not an enzyme) is the classic example of positive cooperativity (nH ≈ 2.8 for O2 binding). Feedback inhibition: the end product of a metabolic pathway acts as an allosteric inhibitor of the first committed step (e.g., CTP inhibiting ATCase in pyrimidine synthesis; isoleucine inhibiting threonine deaminase). Covalent modification provides another layer of regulation: phosphorylation (kinases/phosphatases add/remove phosphate at Ser, Thr, Tyr), acetylation, ubiquitination. Zymogens (proenzymes) are inactive precursors activated by proteolytic cleavage (trypsinogen → trypsin by enteropeptidase; pepsinogen → pepsin by acid; clotting factors).

Cooperativity

Cooperativity describes how ligand binding at one site influences binding at other sites on a multi-subunit protein. Positive cooperativity: binding of the first ligand molecule increases the affinity for subsequent ligand molecules—the binding curve is sigmoidal. This is the molecular basis for hemoglobin's efficient oxygen delivery: in the lungs (high pO2), hemoglobin becomes saturated; in tissues (low pO2), the lowered affinity promotes oxygen release, amplified by the Bohr effect (H+ and CO2 stabilize the T state) and 2,3-BPG (binds the central cavity of deoxyhemoglobin, stabilizing the T state). Negative cooperativity: binding of the first ligand decreases affinity for subsequent ligands—rarer, seen in some receptors. The concerted (MWC) model posits that all subunits are either in the T (low-affinity) or R (high-affinity) state, and the equilibrium shifts with ligand binding. The sequential (KNF) model posits that ligand binding induces a conformational change in the subunit it binds, which then influences neighboring subunits incrementally. The Hill coefficient (nH) quantifies cooperativity from the Hill plot. Practically, nH is calculated from the slope of the Hill plot at half-saturation. An nH equal to the number of binding sites would imply infinite cooperativity (physically impossible); real values are lower. The oxygen-hemoglobin dissociation curve shifts rightward (decreased affinity, easier O2 unloading) with increased temperature, increased CO2, decreased pH (Bohr effect), and increased 2,3-BPG. It shifts leftward (increased affinity, tighter O2 binding) with decreased temperature, decreased CO2, increased pH, and decreased 2,3-BPG. Fetal hemoglobin (HbF, α2γ2) has lower 2,3-BPG affinity than adult hemoglobin (HbA, α2γ2), giving it higher O2 affinity—essential for extracting O2 from maternal blood across the placenta.

Enzyme Experiments

The MCAT frequently presents enzyme kinetics data and asks you to interpret it. Common experimental scenarios: (1) Given a table of V0 at different [S], determine Km and Vmax by fitting to Michaelis-Menten or by Lineweaver-Burk linear regression. (2) Given Lineweaver-Burk plots with and without inhibitor, identify inhibitor type from the intersection pattern. Competitive: intersect at y-axis. Noncompetitive: intersect at x-axis. Uncompetitive: parallel lines. Mixed: intersect between axes. (3) Given a table of kinetic parameters (Km, Vmax, kcat) for wild-type vs. mutant enzymes, interpret which step of catalysis is affected. Increased Km with same Vmax suggests impaired substrate binding. Decreased Vmax with same Km suggests impaired catalytic turnover. (4) Given pH-rate profiles or temperature-rate profiles, interpret the optimal conditions and the loss of activity due to protonation/deprotonation of catalytic residues or denaturation. (5) Given a Dixon plot (1/V0 vs. [I]) or a Cornish-Bowden plot, determine Ki (inhibition constant). (6) Site-directed mutagenesis experiments: replacing a specific residue in the active site decreases kcat but not Km—the residue is involved in catalysis, not binding. Replacing a residue increases Km but kcat is unchanged—the residue is involved in substrate binding. Always distinguish between binding effects (Km changes) and catalytic effects (kcat/Vmax changes).

How it works

Enzyme kinetics distills to three parameters: Km (binding), Vmax (capacity), and kcat/Km (efficiency). The Michaelis-Menten model applies when [S] >> [E] and initial velocity is measured—the hyperbolic V0 vs. [S] curve arises because enzyme active sites become saturated. The Lineweaver-Burk double-reciprocal plot linearizes this relationship, making inhibition patterns visually diagnosable: changes in slope (Km/Vmax), y-intercept (1/Vmax), and x-intercept (−1/Km) reveal the inhibitor's mechanism. Allosteric enzymes escape the Michaelis-Menten framework entirely—they are multi-subunit, exhibit sigmoidal kinetics, and are regulated by effectors that shift the T⇌R equilibrium. The MCAT expects you to move fluidly between these frameworks: is this enzyme Michaelis-Menten or allosteric? What does the inhibitor do to Km and Vmax? What does the mutant tell you about the mutated residue's role?

How it works

Enzyme kinetics distills to three parameters: Km (binding), Vmax (capacity), and kcat/Km (efficiency). The Michaelis-Menten model applies when [S] >> [E] and initial velocity is measured—the hyperbolic V0 vs. [S] curve arises because enzyme active sites become saturated. The Lineweaver-Burk double-reciprocal plot linearizes this relationship, making inhibition patterns visually diagnosable: changes in slope (Km/Vmax), y-intercept (1/Vmax), and x-intercept (−1/Km) reveal the inhibitor's mechanism. Allosteric enzymes escape the Michaelis-Menten framework entirely—they are multi-subunit, exhibit sigmoidal kinetics, and are regulated by effectors that shift the T⇌R equilibrium. The MCAT expects you to move fluidly between these frameworks: is this enzyme Michaelis-Menten or allosteric? What does the inhibitor do to Km and Vmax? What does the mutant tell you about the mutated residue's role?

Comparisons

• B/B (Kinetic graphs): Lineweaver-Burk plots are the single most tested enzyme graph. Know the four inhibition patterns cold: competitive (y-axis intersect), noncompetitive (x-axis), uncompetitive (parallel), mixed (between axes).
• B/B (Allostery in metabolism): PFK-1 (glycolysis) is allosterically activated by AMP and inhibited by ATP and citrate. This is a classic feedback example tested repeatedly.
• C/P (Rate laws): Michaelis-Menten is a specialized rate law. The low-[S] limit (first-order) and high-[S] limit (zero-order) connect to general chemical kinetics.
• B/B (Hemoglobin): Although not an enzyme, hemoglobin's O2-binding cooperativity (Hill coefficient ~2.8) and allosteric regulation (Bohr effect, 2,3-BPG) are tested as enzyme-analogous systems.
• B/B (Covalent regulation): Phosphorylation cascades (kinase/phosphatase) and zymogen activation are recurring regulatory motifs in signal transduction, metabolism, and digestion.
• C/P (Thermodynamics): Enzymes lower Ea but do not change ΔG or Keq. This thermodynamic constraint is fundamental—an enzyme cannot make an endergonic reaction exergonic.

Common confusions

• Confusing what enzymes do and do NOT change. Enzymes lower activation energy (Ea) ONLY. They do NOT change ΔG, ΔH, ΔS, Keq, or the equilibrium position. They accelerate both forward and reverse reactions equally.
• Misreading Lineweaver-Burk intersection points. Competitive = same Vmax, lines meet at y-axis (1/Vmax). Noncompetitive = same Km, lines meet at x-axis (−1/Km). Uncompetitive = parallel. Mixed = intersection elsewhere. This is pure memorization that costs points if confused.
• Thinking Km is simply the dissociation constant. Km = (k₋₁ + kcat)/k₁. Only when kcat is negligible compared to k₋₁ does Km approximate the dissociation constant Kd. The MCAT may exploit this distinction.
• Forgetting that Vmax depends on [E]total. Adding more enzyme increases Vmax proportionally but does NOT change Km. A passage describing 'adding more enzyme' to increase rate is testing this distinction.
• Assuming all inhibitors are competitive. The MCAT loves giving you a Lineweaver-Burk plot with noncompetitive or uncompetitive inhibition because students default to competitive.
• Not recognizing that irreversible inhibitors reduce [E]effective, which lowers Vmax without changing Km—looking deceptively like noncompetitive inhibition. Aspirin, penicillin, and organophosphates are irreversible.
• Mixing up allosteric activators and inhibitors. Activators shift the curve left (increase apparent affinity, lower K0.5). Inhibitors shift right (decrease apparent affinity). The sigmoidal shape persists; the midpoint shifts.
• Misapplying Michaelis-Menten to allosteric enzymes. Allosteric enzymes do NOT follow Michaelis-Menten kinetics—they give sigmoidal curves. Applying MM equations to allosteric data is a trap.

Quick review

• Enzymes lower activation energy (Ea). Do NOT change ΔG, Keq, ΔH, or ΔS. Accelerate both forward and reverse reactions equally.
• Michaelis-Menten: V0 = Vmax[S]/(Km + [S]). Km = [S] at Vmax/2 (apparent affinity). Vmax = maximum velocity at saturating [S].
• kcat = Vmax/[E]total = turnover number (s⁻¹). Catalytic efficiency = kcat/Km (M⁻¹s⁻¹). Diffusion limit ~10^8.
• Lineweaver-Burk: 1/V0 = (Km/Vmax)(1/[S]) + 1/Vmax. Slope = Km/Vmax, y-intercept = 1/Vmax, x-intercept = −1/Km.
• Competitive inhibitor: Km↑, Vmax unchanged. LB: lines intersect at y-axis. Binds active site.
• Noncompetitive inhibitor: Km unchanged, Vmax↓. LB: lines intersect at x-axis. Binds allosteric site, E and ES equally.
• Uncompetitive inhibitor: Km↓, Vmax↓. LB: parallel lines. Binds only ES complex.
• Mixed inhibitor: Vmax↓, Km↑ or ↓. LB: lines intersect between axes. Binds E and ES with different affinities.
• Allosteric enzymes: multi-subunit, sigmoidal kinetics (not MM), regulated by effectors at regulatory sites. Concerted (MWC) model: T (less active) ⇌ R (more active).
• Hill coefficient (nH): nH = 1 (no cooperativity), >1 (positive cooperativity), <1 (negative). Hemoglobin nH ≈ 2.8.
• Feedback inhibition: end product inhibits first committed step. Example: CTP inhibits ATCase. Phosphorylation (kinase/phosphatase) covalently regulates enzyme activity.
• pH and temperature optima: enzymes have optimal ranges. Extreme pH/temperature causes denaturation (loss of structure → loss of activity).